A randomized, double-blind, placebo-controlled evaluation of the pharmacodynamics, pharmacokinetics, and safety of DG-051 in patients with a history of MI.

Trial Profile

A randomized, double-blind, placebo-controlled evaluation of the pharmacodynamics, pharmacokinetics, and safety of DG-051 in patients with a history of MI.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs DG 051 (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 May 2012 Additional trial identifier added (DG051CV202), inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
    • 02 May 2012 Actual initiation date 15 Apr 2008, trial location [Iceland] and official title added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top